Demand for glucagon-like peptide-1 weight-loss drugs — such as Ozempic, Zepbound and Wegovy — coupled with limited insurance ...

Novo Nordisk announced it is cutting ties with telehealth giant Hims & Hers Health, pulling its blockbuster drug Wegovy from the platform after accusing the company of selling “illegitimate, knockoff ...

The researchers first tested their hypothesis by delivering ODN directly to the hindbrain of rats. Once treated, the rats ...

Mini meals with bite size portions are meant to appeal to people taking GLP-1 weight-loss drugs that reduce appetite.

Experts say there’s no evidence GLP-1s can be absorbed through the skin — and these patches don’t contain the FDA-approved ...

When nurse practitioner Amy Rabon launched Sisterhood Sanctuary’s weight management program in 2019, 25 people signed up, ...

More studies are needed, but patients should consider adding exercise and ensure adequate protein intake to maximize the ...

The first human-tested weight-loss drug that burns calories through creatine-based heat generation, without reducing appetite, has successfully completed its Phase I trial.

Amgen AMGN and Novo Nordisk NVO are among the largest companies in the pharmaceutical space. Amgen boasts one of the largest portfolios in the sector, with a strong presence in oncology, ...

According to Research by SNS Insider, The U.S. GLP-1 Receptor Agonist Market to Reach USD 113.13 Billion by 2032, Driven by Rising Prevalence of Type 2 Diabetes and Demand for Obesity-Related ...

"Protein is clearly a subsegment in our food and beverages categories that is growing fast," said PepsiCo CEO Ramon Laguarta ...

At the heart of equitable healthcare lies a critical truth: representation matters.  BlackDoctor.org spoke with Dr. Adrelia ...